Actelion (Actelion) Total Liabilities : $726 Mil (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Actelion Total Liabilities?

Actelion's Total Liabilities for the quarter that ended in Mar. 2017 was $726 Mil.

Actelion's quarterly Total Liabilities increased from Sep. 2016 ($709.21 Mil) to Dec. 2016 ($770.37 Mil) but then declined from Dec. 2016 ($770.37 Mil) to Mar. 2017 ($726.38 Mil).

Actelion's annual Total Liabilities declined from Dec. 2014 ($848.35 Mil) to Dec. 2015 ($602.88 Mil) but then increased from Dec. 2015 ($602.88 Mil) to Dec. 2016 ($770.37 Mil).

Actelion Total Liabilities Historical Data

The historical data trend for Actelion's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actelion Total Liabilities Chart

Actelion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Total Liabilities

Get a 7-Day Free Trial

1,276.07

1,478.56

848.35

602.88

770.37

Actelion Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Total Liabilities	Get a 7-Day Free Trial															609.23	662.10	709.21	770.37	726.38

Actelion Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Actelion's Total Liabilities for the fiscal year that ended in Dec. 2016 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	558.122	+	(0	+	147.089
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	65.163)
	=	770

Total Liabilities	=	Total Assets (A: Dec. 2016 )	-	Total Equity (A: Dec. 2016 )
	=	2066.389	-	1296.015
	=	770

Actelion's Total Liabilities for the quarter that ended in Mar. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	522.392	+	(0	+	148.729
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	55.259)
	=	726

Total Liabilities	=	Total Assets (Q: Mar. 2017 )	-	Total Equity (Q: Mar. 2017 )
	=	2332.191	-	1605.81
	=	726

Actelion Total Liabilities Related Terms

Thank you for viewing the detailed overview of Actelion's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Actelion (Actelion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actelion Ltd (OTCPK:ALIOF) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.actelion.com

Actelion is a Swiss biopharmaceutical firm with several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods of administration. Zavesca is a second-line option for Gaucher disease, and Valchlor treats a rare form of blood cancer. Actelion has created a global commercial infrastructure for its approved orphan drugs and has supplemented its internal pipeline through in-licensing and acquisitions.

Actelion (Actelion) Headlines

From GuruFocus

Jean Hynes Reduces Stake in Actelion

By Kyle Ferguson Kyle Ferguson • 08-03-2016

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 02-14-2017

Actelion Still On Growth Track

By reports.droy reports.droy • 02-18-2015

Eaton Vance Worldwide Health Sciences Fund 4th Quarter Commentary

By Holly LaFon Holly LaFon • 01-24-2017